ELATIVE Efficacy data
With IQIRVO 13x more patients had a biochemical response vs treatment with UDCA alone5*† as well as a rapid and sustained ALP reduction from baseline in just 4 weeks – sustained through to 52 weeks1,5†
IQV-UK-000159 | January 2025

